ReviewBioactive materials2025
Bioprinting for drug screening: A path toward reducing animal testing or redefining preclinical research?
Review in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Computational Modeling Meets 3D Bioprinting: Emerging Synergies in Cardiovascular Disease Modeling.Advanced healthcare materials · 2026Review
- Feasible Regions of Nozzle Temperature, Extrusion Pressure, and Printing Speed in Extrusion-Based Printing Using a Sodium Alginate-Carboxymethylcellulose-Collagen I Bioink.Biomimetics (Basel, Switzerland) · 2026Article
- Engineering the Healing Process: Advanced In Vitro Wound Models and Technologies.Biomedicines · 2026Review
- Balancing Strength and Cell Viability in Gelatin Methacrylate/Gellan Gum Bioink Formulations.ACS omega · 2026Article
- Advances in 3D Bioprinting: Materials, Processes, and Emerging Applications.Micromachines · 2026Review
- Hybrid Dissolving Microneedles Incorporating Hyaluronic Acid Microdepots for Pain-free and Long-acting Corticosteroid Therapy.Biomaterials research · 2026Article
- Artificial intelligence-assisted smart hydrogel bioinks in 3D bioprinting: design, optimization, and construct validation for functional tissue engineering.Frontiers in bioengineering and biotechnology · 2026Review
- Bioprinted skin: from lab bench to clinic, what matters now and what's next.Frontiers in bioengineering and biotechnology · 2026Article
- Advances in 3D bioprinting for medical application: opportunities and challenges.Biomedical engineering online · 2025Review
- High-Throughput 3D Bioprinted Organoids of Skin Cancer Utilized for Diagnosis and Personalized Therapy.Current oncology (Toronto, Ont.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bioprinting is reshaping the field of tissue regeneration and drug screening by creating physiologically accurate and scalable tissue models that reduce the limitations of conventional animal testing. It helps to minimize interspecies variability by developing complex 3D tissue structures that closely mimic the structural and functional characteristics of native tissues, ensuring high reproducibility. Furthermore, it supports more humane and sustainable preclinical testing by aligning with the ethical 3Rs principles (Replacement, Reduction and Refinement). Although bioprinting offers many advantages, its full potential in evaluating drug testing applications has yet to be harnessed. In this review, we discuss the efficacy of key bioprinting techniques in replicating the structural and functional characteristics of engineered tissues, comparing them with their native counterparts. Further, we highlight case studies demonstrating the applications of bioprinted skin, cardiac, hepatic, renal, bone, and cancer models in pharmaceutical research. The commercialization of bioprinted drug testing platforms and their integration into pharmaceutical development are also discussed. Finally, we outline key advantages, current challenges, and future directions needed to establish bioprinting as a transformative tool for preclinical drug testing, aiming to replace traditional animal models.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.